Eric Milner1, Meng-Liang Zhou1, Andrew W Johnson1, Ananth K Vellimana1, Jacob K Greenberg1, David M Holtzman1, Byung Hee Han1, Gregory J Zipfel2. 1. From the Department of Neurological Surgery (E.M., M.-L.Z., A.W.J., A.K.V., J.K.G., B.H.H., G.J.Z.), Program in Neuroscience (E.M.), Department of Neurology (D.M.H., G.J.Z.), Department of Developmental Biology (D.M.H.), and Hope Center for Neurological Disorders (D.M.H., B.H.H., G.J.Z.), Washington University School of Medicine, St. Louis, MO. 2. From the Department of Neurological Surgery (E.M., M.-L.Z., A.W.J., A.K.V., J.K.G., B.H.H., G.J.Z.), Program in Neuroscience (E.M.), Department of Neurology (D.M.H., G.J.Z.), Department of Developmental Biology (D.M.H.), and Hope Center for Neurological Disorders (D.M.H., B.H.H., G.J.Z.), Washington University School of Medicine, St. Louis, MO. zipfelg@wustl.edu.
Abstract
BACKGROUND AND PURPOSE: We and others have shown that soluble amyloid β-peptide (Aβ) and cerebral amyloid angiopathy (CAA) cause significant cerebrovascular dysfunction in mutant amyloid precursor protein (APP) mice, and that these deficits are greater in aged APP mice having CAA compared with young APP mice lacking CAA. Amyloid β-peptide in young APP mice also increases infarction after focal cerebral ischemia, but the impact of CAA on ischemic brain injury is unknown. METHODS: To determine this, we assessed cerebrovascular reactivity, cerebral blood flow (CBF), and extent of infarction and neurological deficits after transient middle cerebral artery occlusion in aged APP mice having extensive CAA versus young APP mice lacking CAA (and aged-matched littermate controls). RESULTS: We found that aged APP mice have more severe cerebrovascular dysfunction that is CAA dependent, have greater CBF compromise during and immediately after middle cerebral artery occlusion, and develop larger infarctions after middle cerebral artery occlusion. CONCLUSIONS: These data indicate CAA induces a more severe form of cerebrovascular dysfunction than amyloid β-peptide alone, leading to intra- and postischemic CBF deficits that ultimately exacerbate cerebral infarction. Our results shed mechanistic light on human studies identifying CAA as an independent risk factor for ischemic brain injury.
BACKGROUND AND PURPOSE: We and others have shown that soluble amyloid β-peptide (Aβ) and cerebral amyloid angiopathy (CAA) cause significant cerebrovascular dysfunction in mutant amyloid precursor protein (APP) mice, and that these deficits are greater in aged APP mice having CAA compared with young APP mice lacking CAA. Amyloid β-peptide in young APP mice also increases infarction after focal cerebral ischemia, but the impact of CAA on ischemic brain injury is unknown. METHODS: To determine this, we assessed cerebrovascular reactivity, cerebral blood flow (CBF), and extent of infarction and neurological deficits after transient middle cerebral artery occlusion in aged APP mice having extensive CAA versus young APP mice lacking CAA (and aged-matched littermate controls). RESULTS: We found that aged APP mice have more severe cerebrovascular dysfunction that is CAA dependent, have greater CBF compromise during and immediately after middle cerebral artery occlusion, and develop larger infarctions after middle cerebral artery occlusion. CONCLUSIONS: These data indicate CAA induces a more severe form of cerebrovascular dysfunction than amyloid β-peptide alone, leading to intra- and postischemic CBF deficits that ultimately exacerbate cerebral infarction. Our results shed mechanistic light on human studies identifying CAA as an independent risk factor for ischemic brain injury.
Authors: K Johnson-Wood; M Lee; R Motter; K Hu; G Gordon; R Barbour; K Khan; M Gordon; H Tan; D Games; I Lieberburg; D Schenk; P Seubert; L McConlogue Journal: Proc Natl Acad Sci U S A Date: 1997-02-18 Impact factor: 11.205
Authors: Andrew Dumas; Gregory A Dierksen; M Edip Gurol; Amy Halpin; Sergi Martinez-Ramirez; Kristin Schwab; Jonathan Rosand; Anand Viswanathan; David H Salat; Jonathan R Polimeni; Steven M Greenberg Journal: Ann Neurol Date: 2012-07 Impact factor: 10.422
Authors: Laibaik Park; Ping Zhou; Rose Pitstick; Carmen Capone; Josef Anrather; Erin H Norris; Linda Younkin; Steven Younkin; George Carlson; Bruce S McEwen; Costantino Iadecola Journal: Proc Natl Acad Sci U S A Date: 2008-01-17 Impact factor: 11.205
Authors: Hans H Dietrich; Chuanxi Xiang; Byung H Han; Gregory J Zipfel; David M Holtzman Journal: Mol Neurodegener Date: 2010-04-13 Impact factor: 14.195
Authors: Daniel Paris; James Humphrey; Amita Quadros; Nikunj Patel; Robert Crescentini; Fiona Crawford; Michael Mullan Journal: Neurol Res Date: 2003-09 Impact factor: 2.448
Authors: John R Cirrito; Patrick C May; Mark A O'Dell; Jennie W Taylor; Maia Parsadanian; Jeffrey W Cramer; James E Audia; Jeffrey S Nissen; Kelly R Bales; Steven M Paul; Ronald B DeMattos; David M Holtzman Journal: J Neurosci Date: 2003-10-01 Impact factor: 6.167
Authors: Aman P Mann; Pablo Scodeller; Sazid Hussain; Gary B Braun; Tarmo Mölder; Kadri Toome; Rajesh Ambasudhan; Tambet Teesalu; Stuart A Lipton; Erkki Ruoslahti Journal: Nat Commun Date: 2017-11-10 Impact factor: 14.919
Authors: Matthew R Reynolds; Itender Singh; Tej D Azad; Brandon B Holmes; Phillip B Verghese; Hans H Dietrich; Marc Diamond; Guojun Bu; Byung Hee Han; Gregory J Zipfel Journal: Mol Neurodegener Date: 2016-01-22 Impact factor: 14.195